Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Systematic validation of predicted microRNAs for cyclin D1

BMC Cancer20099:194

DOI: 10.1186/1471-2407-9-194

Received: 18 December 2008

Accepted: 18 June 2009

Published: 18 June 2009

Abstract

Background

MicroRNAs are the endogenous small non-coding RNA molecules capable of silencing protein coding genes at the posttranscriptional level. Based on computer-aided predictions, a single microRNA could have over a hundred of targets. On the other hand, a single protein-coding gene could be targeted by many potential microRNAs. However, only a relatively small number of these predicted microRNA/mRNA interactions are experimentally validated, and no systematic validation has been carried out using a reporter system.

Methods

In this study, we used luciferease reporter assays to validate microRNAs that can silence cyclin D1 (CCND1) because CCND1 is a well known proto-oncogene implicated in a variety of types of cancers. We chose miRanda http://www.microRNA.org as a primary prediction method. We then cloned 51 of 58 predicted microRNA precursors into pCDH-CMV-MCS-EF1-copGFP and tested for their effect on the luciferase reporter carrying the 3'-untranslated region (UTR) of CCND1 gene.

Results

Real-time PCR revealed the 45 of 51 cloned microRNA precursors expressed a relatively high level of the exogenous microRNAs which were used in our validation experiments. By an arbitrary cutoff of 35% reduction, we identified 7 microRNAs that were able to suppress Luc-CCND1-UTR activity. Among them, 4 of them were previously validated targets and the rest 3 microRNAs were validated to be positive in this study. Of interest, we found that miR-503 not only suppressed the luciferase activity, but also suppressed the endogenous CCND1 both at protein and mRNA levels. Furthermore, we showed that miR-503 was able to reduce S phase cell populations and caused cell growth inhibition, suggesting that miR-503 may be a putative tumor suppressor.

Conclusion

This study provides a more comprehensive picture of microRNA/CCND1 interactions and it further demonstrates the importance of experimental target validation.

Background

Accumulating evidence indicates that microRNAs could play a fundamental role in regulation of diverse cellular pathways including differentiation, proliferation and apoptosis [1, 2]. Thus, deregulation of microRNAs affects normal cell growth and development, leading to a variety of disorders including human malignancies, which have been demonstrated in both in vitro and in vivo systems [1, 36]. Importantly, tumor cells often express a unique set of microRNAs (or microRNA signature). For example, the overall microRNA expression profile of normal tissues is distinct from that of tumor tissues [7] and moreover, microRNA signatures are able to accurately identify cancer tissue origin [8]. MicroRNAs can function as tumor suppressors or oncogenes depending on whether they specifically target oncogenes or tumor suppressor genes [911]. For instance, tumor suppressive microRNAs such as let-7, miR-15 and miR-16 are downregulated or deleted in lung cancer and leukemia [1113]. In contrast, oncogenic microRNAs, such as miR-21 and miR-155, are overexpressed in tumors or tumor cell lines [7, 14, 15].

Since microRNAs are capable of silencing gene expression by binding to the 3'-untranslated region (3'-UTR) with partial sequence homology, a single microRNA usually has multiple targets [16]. Thus, microRNAs could regulate a large fraction of protein-coding genes. As high as 30% of all genes could be microRNA targets [17, 18]. In essence, microRNAs can be considered to be modulators of gene regulators and they can cooperate with transcription factors. Together, microRNAs and transcription factors determine gene expression patterns in the cell [19].

Despite the tremendous progress made in the past several years in identification of microRNAs and their role in diverse cellular functions, the mechanism of microRNA-mediated tumorigenesis is still poorly understood presumably because we do not have a clear picture as to how microRNAs silence their target genes. Given the nature of microRNA targeting, a single protein coding gene (mRNA) can be targeted by multiple microRNAs. For example, CCND1 can be potentially targeted by as many as several dozens of microRNAs depending on which prediction method is used. However, it is not clear how many microRNAs actually can target CCND1. Since CCND1 is a key gene controlling cell cycle and it is frequently overexpressed in cancer cells, contributing to cell proliferation and migration [20], we thought that CCND1 would be an idea gene for microRNA target validation because a few microRNAs have been previously validated, such as miR-17/20 [21], miR-16 family [22, 23], and let-7 [24]; and a relatively large number of microRNAs are predicted to target CCND1.

Therefore, we attempted to validate these predicted microRNAs in a biological reporter system. We found 7 microRNAs are positive to CCND1. In addition to previously validated microRNAs, we found that miR-503 can cause cell cycle arrest and growth inhibition through in part silencing CCND1. To our knowledge, this is the first systematic target validation effort using the biological reporter system and thus, it is expected to provide more comprehensive view of how microRNAs regulate this important gene.

Methods

Cell Culture and Reagents

Human head and neck carcinoma cell line UMSCC10B has been described previously [25] and was grown in DMEM (Cambrex, Walkersville, MD) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, Mo), 2 mM-glutamine, 100 units of penicillin/ml and 100 μg of streptomycin/ml (Cambrex). The cultivation of immortalized kidney epithelial cells 293T (ATCC) has been previously described [26]. All cells were incubated at 37°C in a humidified chamber supplemented with 5% CO2.

Scrambled LNA (locked nucleic acid) oligonucleotide and anti-miR-503 LNA oligonucleotide were purchased from IDT (Coralville, IA). Primary anti-CCND1 antibody (Epitomics, Burlingame, CA) and anti-β-actin antibody (Sigma. St. Louis, Mo) were used in western blot. Secondary antibodies conjugated with IRDye 800CW were purchased from LI-COR Biosciences (Lincoln, NE). PCR primers were purchased from Sigma-Genosys (Woodland, TX) or IDT.

Plasmid constructs

To construct pre-microRNA expression vectors, we first amplified ~0.5 kb DNA fragment covering a pre-microRNA, using genomic DNA from a healthy blood donor as a template. PCR reactions were performed using the high fidelity Phusion enzyme (New England Biolabs Ipswich, MA) and corresponding specific primers as listed in Table 1. The amplified fragment was first cloned into a PCR cloning vector (pCR8) and subsequently cloned a lentiviral vector (pCDH-CMV-MCS-EF1-copGFP from System Biosciences, Mountain View, CA) at EcoR1 and Not1 sites. Where there was an internal EcoR1 or Not1 site, partial digestions were performed to obtain the DNA fragment carrying the pre-microRNA. Expression of the mature microRNAs was verified by QuantiMir kit (System Biosciences) or TaqMan real-time PCR kit (Applied Biosystems) [27, 28].
Table 1

Primers used to clone microRNA precursors in this study

MicroRNA

5' primer

3' primer

miR-19a

GCATCTACTGCAGTGAAGGC

GCGGCCGCAGTTTGATTGGGCGACAGG

miR-491

AGATGGCTTTCTGGGTAGCC

GCGGCCGCTAACAGTAACACGTATGGGC

miR-296

CCTCCTTGGAGCTGAGATGG

GCGGCCGCGTGGGAGGTAGGTAAAACTC

miR-532

CATCTGTTCTCGTATGTGTG

GCGGCCGCACGTAAGAGAGGGTTTACC

miR-188

CTTCCCTCTCCAGTGCATAG

GCGGCCGCTCCTGCAGGATCCATGTAAG

miR-579

CAGTGACAGAGTTGTGTAAC

GCGGCCGCGTGGAAACAAGTTGCATGTC

miR-501

AGACCCTCAAGTGTGATCTG

GCGGCCGCAGTATATGCAGGGGCAATG

miR-548c

TCAGGGTTTCACCATGTTGG

GCGGCCGCACAGAGCAAGACTCCATCTC

miR-219-1

CGTTTACTCTAGAGTCCTCG

GCGGCCGCACAGAGGGCTCGTGAAAAGG

miR-340

TGGCTACCTGTTCAGCTTTC

GCGGCCGCAGCAGTTTACCAGAATACCG

miR-519b

CTGGACACAAAACTCAGGAG

GCGGCCGCGTCTGGGTCACAGAGCAAG

miR-155

TGCCTAAAGGTAACAATGTC

GCGGCCGCGGTTGAACATCCCAGTGAC

miR-519e

GGTATGTGTGGTAGGCTTTG

GCGGCCGCAACTAGCCTAAGAGGTCTAG

miR-515-1

TACATGCCACCACAGGCGGC

GCGGCCGCCTGGGCCACAGAGAGAGAC

miR-139

GATCGTGCAGGCAACTCTTG

GCGGCCGCTGGATAACAAGGCAGTATGG

miR-494

TTCCCGGGCAACCTCTTTTC

GCGGCCGCTCCTTCAACCACAGAAGCAC

miR-203

CGTCTAAGGCGTCCGGTACG

GCGGCCGCTTCCCACAGCACAGCCCGGC

miR-142

GATGGGGTGGAGCCTTTAGG

GCGGCCGCAACCAGGAAGGGCAGGAAAG

miR-450-1

TGATTATCTCTGAGTTGTGG

GCGGCCGCAAAATGATCCCAATACAC

miR-193a

AGTTTCTCGGCGCATAACTC

GCGGCCGCTATTTCTCCAGCGAAGTG

miR-193b

GTTGTCCGGGAAGCTTTTAG

GCGGCCGCCCTCGAAGGGACCTTTTAG

miR-487b

TGGTCTGGGTCCCTGCTTCC

GCGGCCGCAGTCATAAAACCACCACCAC

miR-487a

CAGTCTCATGAGGGAGTGCC

GCGGCCGCTCTCACTGGTCAACTTCCC

miR-301

AGGGCTTGTTTTACATGGCG

GCGGCCGCCAGACGTGTTTCATAATGC

miR-130a

CTGCTTTAGTGGGTCCTGTC

GCGGCCGCTAACGGAGGCAGTGTCTATC

miR-130b

GTCAAAGCATCTGGGACCAG

GCGGCCGCACCTGATCCTCTGATGGAG

miR-148a

CTTTGCTGTGACATTGCGAC

GCGGCCGCTTTGGGGGGATTTTGTTCCC

miR-503

CTCGTGGGGAAGGTAGAAGG

GCGGCCGCAAGATAGGTTTTCTTCGTTG

miR-152

AGCAGCCAACTCAGAACTCG

GCGGCCGCAAGGTCCACAGCTGGTTCTG

miR-95

CCTCCTGAGGAATCCAGGCG

GCGGCCGCGATCGGGCCCTTGCGAAGCC

miR-550

GAGCCTTCTAACCACAACCC

GCGGCCGCATAAAGCAGTTCCTACACTC

miR-545

TCATGCCAGTGTCTAGTTCC

GCGGCCGCCACCAAGAAAGCAAGTGTC

miR-424

ACCCACTACGTTGTTCCAAG

GCGGCCGCAGAGCACCGATCGCTCACTG

miR-15a

AAAGGTGTACTGCAAGGAAC

GCGGCCGCACTGCTGACATTGCTATC

miR-16

GCTAGGTTGGATGAATCCTAC

GCGGCCGCCATCCAAAGTGTTACAAAG

miR-497

CCTGAGCTGAGTTCCTACAG

GCGGCCGCGTGTGGGCAACAAAGACTCC

miR-195

GTGACACAAAAAACATCTGG

GCGGCCGCATAAGCATCTGCCCCCAACC

miR-515-2

CGAGTAGCTGGGACTACAGG

GCGGCCGCATACCAGCTACTCGGGAGGC

miR-144

ATTACGCCATCTCTGGCTTG

GCGGCCGCACGTTTTCTGGGTATAGC

miR-34a

ATGGAGTCTTGCTAGTTGCC

GCGGCCGCTACGTGCAAACTTCTCCCAG

miR-449a

TTGAAGTAATACATTTTGTG

GCGGCCGCACTGTCTACTCCGAAAGAC

miR-146a

GTAGAGACAAATTCTCCATG

GCGGCCGCTTTCTCACAGGAACTCACAC

miR-655

AATCCGTGGAGGAAGCTTTC

GCGGCCGCACAGCAAACACAGCAAAGC

miR-374

GTTCCTTTATTGGAAGTCTG

GCGGCCGCAGGCACACAATAAATGTTTG

miR-524

AGTAGAGACAGGGTTTCACC

GCGGCCGCGATAGAGAGACTCTGTCCGC

miR-520d

CTGGTGTCTAACTCCTGAGA

GCGGCCGCTGACCATTTGAAGCCAAGAG

miR-376a-1

CCTGAGTAGGTGCAAAGATG

GCGGCCGCATTATGTGTGCACCAAGGGC

miR-23b

AATTGTGTGTGTCGCATGGC

GCGGCCGCGGTGCAGAACTTAGCCACTG

miR-23a

GCCATGCAAGTTGCTGTAGC

GCGGCCGCTTCCTGCTGAACTGAGCCAG

miR-199a-2

AGCGCATACCCAAACCTCCC

GCGGCCGCGTCAAGAAGGCCTTACCCGC

miR-199b

GGGGTTGGACACTAGGTAGG

GCGGCCGCAGGTTTTGGGGTGAGGGAGG

miR-194-1

CTAATGGCATTATCTCACAG

GCGGCCGCGATGACTTTAATCCTCTTCC

miR-202

CCTGCGCATAAATGTGGAGC

GCGGCCGCTCCTCTCTGCATCCTGGGTC

miR-875

TATACCTCAGTTTTATCAGGTG

GCGGCCGCGTGCATAGCTTCTGTAAAGG

miR-511-1

AATGGCCTCTAGTTGCATCC

GCGGCCGCATAGATCACTTACCTGAGGG

The luciferase-UTR reporter plasmids (Luc-CCND1-3'-UTR-1 and Luc-CCND1-3'-UTR-2) were constructed by introducing the CCND1 3'-UTR carrying putative microRNA binding sites into pGL3 control vector (Promega, Madison, WI). Thus, we amplified the CCND1 3'-UTR sequence from MCF10A cDNA by PCR using the primers as follows.

CCND1-UTR-5.2 (sense) 5'-GGGCGCCAGGCAGGCGGGCGC (1–21)CCND1-UTR-Not1-3.2 (antisense) 5'-GCGGCCGCTGGTTTTAGAATATGAAGAAG (981–1002) for Luc-CCND1-3'-UTR-1.

CCND1-UTR-5.3 (sense) 5'-ACGTCCAGGTTCAACCCACAG (944–965)CCND1-UTR-Not1-3.4 (antisense) 5'-GCGGCCGCGTCTTTTTGTCTTCTGCTGGA (3134–3155) for Luc-CCND1-3'-UTR-2. Using the same strategy, the amplified fragments were then cloned into the modified pGL3 where EcoR1 and Not1 sites were introduced so that the UTR sequences were unidirectionally cloned downstream the luciferase gene.

To delete miR-503 binding sites, we used a two step PCR procedure. In the first PCR reaction, 2 sets of primers CCND1-UTR-5.3 and CCND1-UTR-3.6 ACAAAAAACTGATCCTCCAAGCTGCGGCCTGTCCCCGGTGT; CCND1-UTR-5.6 ACACCGGGGACAGGCCGCAGCTTGGAGGATCAGTTTTTTGT (complementary to CCND1-UTR-3.6) and CCND1-UTR-Not1-3.4 were used to generate two overlapping PCR products where the miR-503 binding sites were deleted. In the second PCR reaction, we used these two products as templates and primers CCND1-UTR-5.3 and CCND1-UTR-Not1-3.4. Finally, the PCR product was cloned into the pGL3 control vector as above. All PCR products were verified by DNA sequencing.

Transfection

UMSCC10B or 293T cells were transfected using DNAfectin reagent (Applied Biological Materials, British Columbia, Canada) following the manufacturer's protocol. In brief, cells were seeded at 40% confluence in a 12-well plate and then transfected with 1 μg of plasmid DNA in serum free medium the following day when the cells reached about 70% confluence. The serum free media was then replaced by normal growth medium after 16 h of transfection.

Luciferase Assay

Luciferase assays were carried out in 293T cells to determine the effect of microRNAs on the activity of Luc-CCND1-3'-UTR and the deletion mutant constructs. First, cells were transfected with appropriate plasmids in 12-well plates. Then, the cells were harvested and lysed for luciferase assay 24 h after transfection. Luciferase activity was determined by using a luciferase assay kit (Promega) according to the manufacturer's protocol. Renilla luciferase was used for normalization.

PCR/RT-PCR and real-time RT-PCR

PCR was performed to amplify pre-microRNA sequences or the CCND1 3'-UTR sequence according to the standard three-step procedure. Annealing temperature varied depending on the primers used. For RT-PCR, we isolated total RNA using Trizol reagent (Invitrogen) per the manufacturer protocol and used 1 μg RNA to synthesize cDNA by SuperScriptase III (Invitrogen) with random primers. Finally, the resultant cDNA was used in regular PCR or real-time PCR reactions. To detect CCND1 mRNA levels, we used the SYBR Green method with primers CCND1-5.1 and CCND1-3.1.

CCND1-5.1 (sense) 5'-CAGGAGAGGAAAGCATGGAG

CCND1-3.1 (antisense) 5'-TCGGGTGAAATAATGGTGGT

To detect mature microRNA expression, we also used Trizol reagent to isolate total RNA. Real-time PCR reactions were performed in ABI 7500 HT thermal cycler according to the manufacturer's protocol. Average levels of U6, 5s RNA and β-actin were used as an internal control. The fold-change between vector control and pre-microRNA expression vector was calculated with the 2-ΔΔCt method [27, 28].

Cell growth inhibition assay

Cell growth assays were carried out by MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] as described previously [29]. In brief, cells were seeded in 96-well plates and incubated for various days before adding MTT. Absorbance at 570 nm was measured in the multi well plate reader (Thermo Scientific, Waltham, MA). The relative values were calculated by expressing the value at the first day as 1.

Western Blot

Cells were harvested and protein was extracted 2 days after transfection as previously described [26]. Protein concentration was determined by protein assay kit (Bio-Rad, Hercules, CA) and samples were separated in 12% SDS polyacrylamide gels. Signals were revealed by a secondary antibody labeled with IRDye 800CW and the signal intensity was determined by Odyssey Infrared Imaging System (LI-COR Biosciences).

Cell cycle analysis

Cell cycle analysis was performed using the standard propidium iodide method. In brief, UMSCC10B cells were first transfected with either vector control or miR-503 expression vector. One day later, cells were then split and grown for 24 h before harvesting for cell cycle analysis. After fixing at 70% ethanol, the cells were stained with propidium iodide along with RNase A. Finally, the cells were analyzed by FACS Vantage flow cytometer (Becton-Dickinson).

Statistical analysis

Statistical analysis of data was performed using the Student's t test. Differences with p values less than 0.05 are considered significant.

Results

To determine microRNA regulation of CCND1, we searched for putative microRNAs that are able to target CCND1 based on commonly cited prediction programs such as miRanda [30]http://www.microrna.org and TargetScan4 http://www.targetscan.org[31], PicTar http://pictar.mdc-berlin.de/[32]. Apparently, different programs may predict different microRNAs for a given coding gene. We used miRanda as a primary source in this study. Based on January 2008 Release version, we found a total of 58 microRNAs that potentially target CCND1 (Fig. 1). To obtain a comprehensive picture of microRNA targeting for CCND1, we made an attempt to test all 58 predicted microRNAs.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-9-194/MediaObjects/12885_2008_Article_1528_Fig1_HTML.jpg
Figure 1

The CCND1 3'-UTR with predicted microRNAs and luciferase constructs. The CCND1 3'-UTR sequences (3207 bp) is based on NM_053056. Three microRNAs identified to be positive to CCND1 in this study are indicated in green with relative positions. Those previously validated microRNAs are indicated in red. See Table 2 for detail positions.

We first cloned all of these microRNA precursors into pCDH-CMV-MCS-EF1-copGFP (pCDH, System Biosciences, Mountain View, CA) expression vector. As indicated in Fig. 2A, the pre-microRNAs were expected to express under control of the CMV promoter and eventually processed into mature microRNA by the cellular Drasha and Dicer. Since this vector also carried green fluorescent protein (GFP) tag, transfection rate can be easily monitored under a fluorescence microscope. We were able to clone 51 of 58 microRNAs and then introduced into 293T cells. Two days after transfection, RNA was isolated, followed by real time RT-PCR analysis, which revealed that 45 of them gave rise to a higher level of mature microRNAs over the endogenous counterpart (vector control) (Table 2). On average, the exogenous microRNAs were up to a 100-fold higher than the endogenous microRNAs. The variations among different microRNAs are also in part due to variations in the levels of endogenous microRNAs. Therefore, the majority of these microRNAs were highly expressed. Shown in Fig. 2B were three microRNAs (miR-19a, miR-155 and miR-503) that were ectopically expressed because these three microRNAs were capable of suppressing Luc-CCND1-3'-UTR as demonstrated in this study (Fig. 3).
Table 2

Ectopic expression of microRNAs

Name

Vector

Vector IC

miR

miR IC

V:DCT

miR:DCT

DDCT

Fold change

19a

20.1

14.5

18.4

14.1

5.6

4.3

-1.2

2.4

491-3p

24.4

14.3

22.0

14.2

10.1

7.8

-2.4

5.1

296-3p

22.8

14.5

17.3

14.1

8.3

3.1

-5.2

36.1

532-3p

22.0

14.3

20.5

14.2

7.7

6.2

-1.5

2.9

188-3p

25.0

14.5

21.4

15.0

10.6

6.4

-4.2

17.9

579

27.3

14.5

23.3

14.1

12.9

9.2

-3.7

12.8

501-5p

23.0

14.5

19.2

14.1

8.5

5.1

-3.4

10.7

548c-3p

26.7

14.5

24.8

14.1

12.3

10.7

-1.6

3.1

219-1-3p

26.0

14.5

19.4

14.4

11.5

5.0

-6.5

92.9

519b-3p

28.6

14.3

22.9

14.2

14.3

8.7

-5.6

48.8

155

33.6

17.1

25.3

17.5

16.5

7.8

-8.7

415.9

519e

28.6

14.3

22.9

14.2

16.0

8.7

-7.3

155.0

139-3p

24.4

14.5

16.7

13.7

9.9

3.0

-6.9

118.5

203

26.2

14.5

15.3

14.1

11.7

1.2

-10.5

1436.2

142-3p

31.9

14.5

21.2

14.1

17.5

7.1

-10.3

1296.1

450b-5p

21.3

14.5

17.3

15.0

6.9

2.3

-4.5

23.2

193a-3p

24.9

14.5

19.0

14.4

10.4

4.7

-5.8

55.1

193b

24.0

14.3

20.3

14.1

9.7

6.2

-3.5

11.5

487b

26.3

14.3

17.6

14.1

12.1

3.4

-8.6

391.9

487a

28.3

14.5

19.0

15.0

13.9

4.1

-9.8

900.1

301a

25.1

14.5

22.0

15.0

10.6

7.1

-3.6

11.8

130a

25.0

14.3

16.1

14.1

10.8

2.0

-8.8

431.6

130b

20.4

14.5

17.4

14.3

5.9

3.2

-2.7

6.5

148a

21.1

14.7

16.6

14.6

6.4

2.0

-4.2

18.1

503

24.8

18.6

20.4

18.1

6.2

2.3

-3.9

14.5

152

24.2

14.5

15.5

14.1

9.7

1.4

-8.4

327.0

95

23.4

14.5

16.0

14.2

8.8

1.8

-7.0

128.3

550

21.7

14.5

16.1

14.4

7.2

1.7

-5.5

44.7

424

18.0

14.5

14.6

14.3

3.5

0.4

-3.1

8.5

16

16.8

14.3

15.6

14.2

2.5

1.4

-1.2

2.3

195

17.3

14.3

15.2

14.2

3.0

1.0

-2.1

4.2

144

30.1

14.5

24.2

14.2

15.6

10.0

-5.6

47.0

34a

27.4

15.5

19.0

14.6

11.9

4.4

-7.5

187.3

449a

25.2

14.3

15.6

14.2

10.9

1.4

-9.5

723.8

146a

34.6

14.5

25.6

14.5

20.1

11.1

-9.0

505.0

655

29.7

14.5

27.4

14.2

15.2

13.3

-1.9

3.8

374b

19.5

14.5

16.8

14.2

5.0

2.7

-2.3

5.1

520d-5p

31.8

14.5

25.8

13.7

17.3

12.1

-5.2

36.8

376c

29.3

14.5

18.7

14.1

14.9

4.6

-10.3

1296.1

23b

19.2

14.3

18.0

14.2

4.9

3.7

-1.2

2.2

199a-3p

27.6

14.5

17.5

14.1

13.1

3.4

-9.8

864.1

194

23.7

14.5

17.4

14.1

9.2

3.2

-6.0

62.4

202

31.2

14.5

18.4

13.7

16.7

4.7

-12.0

3959.2

875

23.4

14.5

15.7

13.6

8.8

2.1

-6.7

104.5

511

25.4

14.5

20.5

14.4

10.9

6.1

-4.9

29.1

Values are CTs except for fold change. IC, Internal controls, average of 5sRNA, U6 and β-actin; V, vector.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-9-194/MediaObjects/12885_2008_Article_1528_Fig2_HTML.jpg
Figure 2

Expression of exogenous microRNAs used for validation. A, Schematic description of microRNA constructs. B, Expression of three microRNAs that were identified to be positive in this study. 293T cells were first transfected with indicated miRNAs and harvested 24 h after infection for extraction of RNA. The relative expression was determined by real-time PCR. Values are means of three transfection experiments.

https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-9-194/MediaObjects/12885_2008_Article_1528_Fig3_HTML.jpg
Figure 3

Validation of seven microRNAs capable of silencing CCND1. 293T cells were transfected with indicated Luc-CCND1-3'-UTR along with corresponding miRNAs and harvested 24 h after transfection for luciferase assays as detailed in Materials and Methods. Values are means ± SE of three transfection experiments. **, p < 0.01.

Next, we cloned the CCND1 3'-UTR (NM_053056). As indicated in Fig. 1, the CCND1 3'-UTR was about 3207 bp in length with corresponding microRNA sites. Since this fragment was relatively long, we divided it into two fragments and separately cloned into pGL3 control vector, generating Luc-CCND1-3'-UTR-1 and Luc-CCND1-3'-UTR-2, which were overlapped by 58 bps. Having demonstrated ectopic expression of these microRNAs and construction of CCND1-3'-UTR luciferease reporters, we introduced each of microRNAs listed in Table 2 into 293T cells along with Luc-CCND1-3'-UTR-1 or Luc-CCND1-3'-UTR-2. Luciferase assays indicated that although the majority of microRNAs had no effect on its luciferase activity, a total of seven microRNAs, miR-19a, miR-153, miR-503, miR-16, miR-34a, miR-195 and miR-424a suppressed its luciferase activity by over 35% (Fig. 3). Among those microRNAs, miR-16, miR-34a, miR-195 and miR-424a were previously reported to suppress CCND1 [22, 23, 33]. On the other hand, miR-19a, miR-155, and miR-503 have not been previously validated to target CCND1. Therefore, we further characterized these three microRNAs.

To further demonstrate that these microRNAs truly target CCND1, we determined whether they are able to suppress the endogenous CCND1 protein levels. Western blot analysis indicated that only miR-503 was able to suppress CCND1 protein by over 40% (Fig. 4A and 4B) in UMSCC10B cells in addition to its ability to suppress the luciferase activity (Fig. 4D). Moreover, we examined the CCND1 mRNA by real time PCR and found that only miR-503 significantly reduced CCND1 mRNA (Fig. 4C). These results suggest that miR-503 is a true microRNA for CCND1 whereas it remains to be determined for their targeting capability for the other two microRNAs.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-9-194/MediaObjects/12885_2008_Article_1528_Fig4_HTML.jpg
Figure 4

Suppression of the endogenous CCND1 by miR-503. A and B, Western blot revealing reduction of CCND1 protein in miR-503 transfected UMSCC10B cells with quantitative measurement of three experiments (B). C, The same miR-503 transfected UMSCC10B cells were subject to RNA extraction and real time PCR analysis. D. Luciferase assays in UMSCC10B cells. Values in B, C and D are means ± SE of three separate experiments. **, p < 0.01. Expt, Experiment.

To confirm that suppression of CCND1 is specific to miR-503, we transfected the cells with anti-miR-503 along with the reporter. In contrast to miR-503, anti-miR-503 caused an increase in the luciferase activity compared to the scrambled oligo (Fig. 5). To determine the importance of two miR-503 binding sites, we deleted these two sites. This deletion substantially impaired its suppression activity, suggesting that these two putative bindings are important for miR-503-mediated suppression.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-9-194/MediaObjects/12885_2008_Article_1528_Fig5_HTML.jpg
Figure 5

Effect of anti-miR-503 and miR-503 binding sites on the Luc-CCND1-3'-UTR activity. 293T cells were transfected with Luc-CCND1-3'-UTR-2 along with either scrambled oligo or anti-miR-503 and the harvested for luciferase assays 24 h after transfection. To determine the importance of miR-503 binding sites, the same cells were transfected with Luc-CCND1-3'-UTR-2-d, in which the miR-503 binding sites were deleted. Along with the reporter Luc-CCND1-3'-UTR-2-d was either vector or miR-503. Values are means ± SE of three separate experiments. **, p < 0.01; n.s., not significant.

Given that CCND1 is a key protein regulating cell cycle, we then determined whether suppression of CCND1 by miR-503 has any effect on cell cycle. We found that miR-503 slightly increased G1 phase populations, but had more profound effect on S phase populations (Fig. 6A). Based on average of three separate experiments, suppression of S phase populations by miR-503 was statistically significant (Fig. 6B). While the vector control revealed 25% of S phase populations, miR-503 cells revealed 20% of S1 phase populations. This result is consistent with the previous report that higher levels of CCND1 are associated with higher S phase populations in cancer cells [34].
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-9-194/MediaObjects/12885_2008_Article_1528_Fig6_HTML.jpg
Figure 6

Effect of miR-503 on cell cycle and cell growth. A, A representative cell cycle profile for vector control or miR-503 in UMSCC10B cells. B, Average of S phase populations. C, While miR-503 suppresses, anti-miR-503 increases cell growth. UMSCC10B cells were transfected with vector or miR-503, or scrambled oligo or anti-miR-503 and then grown for 4 days before MTT assays. Values in C are means ± SE of three separate experiments. **, p < 0.01; *, p < 0.05.

Suppression of CCND1 by miR-503 is expected to reduce cell growth. Therefore, we determined the effect of miR-503 on cell growth by MTT assays. As shown in Fig. 6C, miR-503 suppressed cell growth by about 31% compared to vector control. On the other hand, anti-miR-503 enhanced cell growth by about 30%.

Discussion

Although there are numerous computer-aided algorithms for prediction of microRNA targets, these predicted targets remains to be experimentally validated and how many microRNAs can actually target a single gene is not clear. Our study suggests that the ratio of true target/predicted target is relatively low in our system, and further suggest the complexity of the microRNA/mRNA interactions. There are numerous putative target genes for a given microRNA. Similarly, for given protein coding gene, there are often many putative microRNAs. Therefore, it would be of merit to determine how many microRNAs can actually target a given gene. We chose CCND1 for two reasons. First, it is a well known proto-oncogene that is implicated in tumorigenesis. Second, CCND1 has a relative long UTR so that a relative large number of putative microRNAs can target it, which would allow us to make a good assessment of microRNA targeting.

Among the 58 predicted microRNAs, we cloned 51 of them. We found that 6 microRNA precursors did not express sufficient amount of exogenous microRNAs. Therefore, these microRNAs were excluded from validation. Among 45 microRNAs tested there were seven microRNAs found to be positive based on luciferase assays by arbitrary cutoff of 35% reduction. Thus, the positive ratio for tested microRNAs is about 16%. Although some other microRNAs such as let-7b and miR-17 were showed to be positive to CCND1 by other groups [21, 24], these microRNAs are not in the miRanda list and thus, they were not tested in this study. As listed in Table 3, the predicted microRNAs can be categorized into 4 groups. The first group consists of 6 microRNAs which are overlapped in all three programs. Four of them have been validated in the literature or in this study. The second group consisting of microRNAs overlapped within miRanda and PicTar; this group has an additional microRNA, i.e., miR-195, which is also positive to CCND1. The third group of microRNAs are overlapped within miRanda and TargetScan4, consisting of 27 microRNAs. Among them, we have validated miR-503 and miR-19a positive to CCND1 by luciferase assays. The fourth group shares no overlapped microRNAs with any of other programs. However, we still found one potential microRNA (miR-424) for CCND1. Based on these comparisons, there appears to be a tendency that the first group gives rise to the highest possibility of positivity and the last group gives rise to the lowest possibility of positivity. However, there is a possibility that functional microRNA might be found in this group, highlighting the necessity of experimental validation.
Table 3

Comparison of predicted CCND1 microRNAs

Group 1 (M, T and P)

miR-15a

miR-15b

miR-16

miR-34a

miR-23a

miR-23b

 

Group 2 (M and P)

miR-15a

miR-15b

miR-16

miR-34a

miR-195

miR-23a

miR-23b

Group 3 (M and T)

miR-15a

miR-15b

miR-16

miR-34a

miR-195

miR-424

miR-503

miR-19a

miR-23a

miR-23b

miR-202

miR-497

miR-193a

miR-193b

miR-449a

miR-511

miR-494

miR-487a

miR-655

miR-95

miR-374b

miR-494

miR-296-3p

miR-548c-3p

miR-548d

miR-548c

miR-520d-5p

 

Group 4 (M only)

miR-155

miR-491-3p

miR-296-3p

miR-532-3p

miR-188-3p

miR-579

miR-501-5p

miR-219-1-3p

miR-340

miR-519b-3p

miR-519e

miR-515-3p

miR-139-3p

miR-203

miR-142-3p

miR-450-5p

miR-487b

miR-301a

miR-301b

miR-130a

miR-130b

miR-148a

miR-152

miR-550

miR-545

miR-497

miR-144

miR-449a

miR-146a

miR-655

miR-374b

miR-524-5p

miR-520d-5p

miR-376c

miR-199a-3p

miR-199b-3p

miR-194

miR-202

miR-875-3p

miR-511

  

*M, miRanda; T, TargetScan4; P, PicTar. microRNAs in bold only were validated in literature; those underlined were validated in both literature and in this study. Those in italicized were validated in this study only.

Given that CCND1 can be targeted by multiple microRNAs, it is our expectation that those microRNAs may simultaneously target CCND1 in the same cell in concert if they are present at the same time. In this case, it would be interesting to determine whether they have a synergistic suppressive effect on CCND1. In addition to the previously identified microRNAs such as miR-16 and miR-34a, we found that microRNAs such as microRNA-503, which have not been previously reported, can also target this gene. Four lines of evidence support that miR-503 specifically targets CCND1. First, ectopic expression of miR-503 suppresses luciferase assays with Luc-CCND1-UTR. Second, anti-miR-503 enhances the activity. Third, miR-503 does not only affect the luciferase activity, but also the endogenous gene, as shown by western blot and real time PCR. Forth, miR-503 suppresses tumor cell growth, consistent with the notion that suppression of CCND1 would inhibit cell growth. Although there is little information available in the literature regarding function of miR-503, our findings suggest that miR-503 is a putative tumor suppressor.

The other two potential microRNAs (miR-19a and miR-155) are also interesting because they show suppression ability for the luciferase activity. However, they do not seem to affect CCND1 protein or mRNA levels, which could be due to the cell type specific effect or artifacts that might be caused by luciferase assays. This remains to be further determined.

In summary, we used a luciferase reporter system and systematically tested miRNAs that are predicted to target CCND1 by a computer-aided prediction method. Our validation results provide a relatively comprehensive picture of miRNA/mRNA interactions. Thus, this information may be valuable for future studies on the regulation of this important gene.

Conclusion

This study suggests that miRNAs can interact with a target mRNA at both conserved and non-conserved sites although the conserved sites give rise to a higher positive ratio than the latter. The overall ratio for positive target sites among the predicted sites is relatively low. However, since it is possible that miRNA/mRNA interactions may depend on the cellular content, this ratio could be different in a different cellular content. Therefore, our study highlights the importance of experimental target validation.

Abbreviations

PCR: 

polymerase chain reaction

RT: 

reverse transcription

UTR: 

untranslated region.

Declarations

Acknowledgements

This work was supported by grants CA102630 from NCI and McElroy Foundation. QJ was supported in part by China Scholarship Counsel of Education Ministry, P.R. China.

Authors’ Affiliations

(1)
Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine
(2)
Institute of Microbiology, College of Life Sciences, Zhejiang University

References

  1. Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell. 2005, 122 (1): 6-7. 10.1016/j.cell.2005.06.036.View ArticlePubMedGoogle Scholar
  2. Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004, 303 (5654): 83-86. 10.1126/science.1091903.View ArticlePubMedGoogle Scholar
  3. Hwang HW, Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006, 94 (6): 776-780. 10.1038/sj.bjc.6603023.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Hammond SM: MicroRNAs as oncogenes. Curr Opin Genet Dev. 2006, 16 (1): 4-9. 10.1016/j.gde.2005.12.005.View ArticlePubMedGoogle Scholar
  5. Esquela-Kerscher A, Slack FJ: Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6 (4): 259-269. 10.1038/nrc1840.View ArticlePubMedGoogle Scholar
  6. Gregory RI, Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res. 2005, 65 (9): 3509-3512. 10.1158/0008-5472.CAN-05-0298.View ArticlePubMedGoogle Scholar
  7. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65 (16): 7065-7070. 10.1158/0008-5472.CAN-05-1783.View ArticlePubMedGoogle Scholar
  8. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008, 26 (4): 462-469. 10.1038/nbt1392.View ArticlePubMedGoogle Scholar
  9. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005, 102 (39): 13944-13949. 10.1073/pnas.0506654102.View ArticlePubMedPubMed CentralGoogle Scholar
  10. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005, 435 (7043): 839-843. 10.1038/nature03677.View ArticlePubMedGoogle Scholar
  11. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA family. Cell. 2005, 120 (5): 635-647. 10.1016/j.cell.2005.01.014.View ArticlePubMedGoogle Scholar
  12. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64 (11): 3753-3756. 10.1158/0008-5472.CAN-04-0637.View ArticlePubMedGoogle Scholar
  13. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002, 99 (24): 15524-15529. 10.1073/pnas.242606799.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005, 102 (10): 3627-3632. 10.1073/pnas.0500613102.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65 (14): 6029-6033. 10.1158/0008-5472.CAN-05-0137.View ArticlePubMedGoogle Scholar
  16. Brennecke J, Stark A, Russell RB, Cohen SM: Principles of microRNA-target recognition. PLoS Biol. 2005, 3 (3): e85-10.1371/journal.pbio.0030085.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Du T, Zamore PD: microPrimer: the biogenesis and function of microRNA. Development. 2005, 132 (21): 4645-4652. 10.1242/dev.02070.View ArticlePubMedGoogle Scholar
  18. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005, 120 (1): 15-20. 10.1016/j.cell.2004.12.035.View ArticlePubMedGoogle Scholar
  19. Hobert O: Gene regulation by transcription factors and microRNAs. Science. 2008, 319 (5871): 1785-1786. 10.1126/science.1151651.View ArticlePubMedGoogle Scholar
  20. Li Z, Wang C, Prendergast GC, Pestell RG: Cyclin D1 functions in cell migration. Cell Cycle. 2006, 5 (21): 2440-2442.View ArticlePubMedGoogle Scholar
  21. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X, Hyslop T, et al: A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol. 2008, 182 (3): 509-517. 10.1083/jcb.200801079.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, Zheng X: miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008, 36 (16): 5391-5404. 10.1093/nar/gkn522.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008, 14 (11): 1271-1277. 10.1038/nm.1880.View ArticlePubMedGoogle Scholar
  24. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008, 18 (5): 549-557. 10.1038/cr.2008.45.View ArticlePubMedGoogle Scholar
  25. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA: Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol. 1981, 107 (11): 703-710.View ArticlePubMedGoogle Scholar
  26. Zhu S, Si ML, Wu H, Mo YY: MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1). J Biol Chem. 2007, 282 (19): 14328-14336. 10.1074/jbc.M611393200.View ArticlePubMedGoogle Scholar
  27. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005, 33 (20): e179-10.1093/nar/gni178.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Lao K, Xu NL, Yeung V, Chen C, Livak KJ, Straus NA: Multiplexing RT-PCR for the detection of multiple miRNA species in small samples. Biochem Biophys Res Commun. 2006, 343 (1): 85-89. 10.1016/j.bbrc.2006.02.106.View ArticlePubMedGoogle Scholar
  29. Wu F, Chiocca S, Beck WT, Mo YY: Gam1-associated alterations of drug responsiveness through activation of apoptosis. Mol Cancer Ther. 2007, 6 (6): 1823-1830. 10.1158/1535-7163.MCT-06-0771.View ArticlePubMedGoogle Scholar
  30. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human MicroRNA targets. PLoS Biol. 2004, 2 (11): e363-10.1371/journal.pbio.0020363.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP: MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007, 27 (1): 91-105. 10.1016/j.molcel.2007.06.017.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al: Combinatorial microRNA target predictions. Nat Genet. 2005, 37 (5): 495-500. 10.1038/ng1536.View ArticlePubMedGoogle Scholar
  33. Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, Sun Z, Zheng X: Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008, 582 (10): 1564-1568. 10.1016/j.febslet.2008.03.057.View ArticlePubMedGoogle Scholar
  34. Chen RW, Bemis LT, Amato CM, Myint H, Tran H, Birks DK, Eckhardt SG, Robinson WA: Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood. 2008, 112 (3): 822-829. 10.1182/blood-2008-03-142182.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/194/prepub

Copyright

© Jiang et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement